

INIM0031: Neoplasia and its Treatment

[View Online](#)

1

Weinberg RA. The biology of cancer. 2nd ed. New York: : Garland Science 2014.

2

Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell 2000;**100**:57-70.
doi:10.1016/S0092-8674(00)81683-9

3

Lazebnik Y. What are the hallmarks of cancer? Nature Reviews Cancer 2010;**10**:232-3.
doi:10.1038/nrc2827

4

Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nature Reviews Cancer 2015;**16**:35-42. doi:10.1038/nrc.2015.4

5

Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nature Reviews Cancer 2015;**16**:20-33. doi:10.1038/nrc.2015.2

6

Shankaran V, Ikeda H, Bruce AT, et al. IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;**410**:1107-11.
doi:10.1038/35074122

7

Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. *Nature* 2007;**450**:903–7. doi:10.1038/nature06309

8

Hodi FS, O'Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *New England Journal of Medicine* 2010;**363**:711–23. doi:10.1056/NEJMoa1003466

9

Robert D. Schreiber, Lloyd J. Old and Mark J. Smyth. Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. *Science* 2011;**331**:1565–70.http://www.jstor.org/stable/29783923?seq=1#page_scan_tab_contents

10

Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New England Journal of Medicine* 2012;**366**:2443–54. doi:10.1056/NEJMoa1200690

11

Grupp SA, Kalos M, Barrett D, et al. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. *New England Journal of Medicine* 2013;**368**:1509–18. doi:10.1056/NEJMoa1215134

12

Robbins PF, Morgan RA, Feldman SA, et al. Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. *Journal of Clinical Oncology* 2011;**29**:917–24. doi:10.1200/JCO.2010.32.2537

13

Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. *Science* 2015;**348**:69–74. doi:10.1126/science.aaa4971

14

Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine* 2016;**22**:26–36. doi:10.1038/nm.4015

15

Morris EC, Stauss HJ. Optimizing T-cell receptor gene therapy for hematologic malignancies. *Blood* 2016;**127**:3305–11. doi:10.1182/blood-2015-11-629071

16

de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. *The Lancet Oncology* 2012;**13**:607–15. doi:10.1016/S1470-2045(12)70137-7

17

zur Hausen H. Papillomaviruses in the causation of human cancers — a brief historical account. *Virology* 2009;**384**:260–5. doi:10.1016/j.virol.2008.11.046

18

Ajila V, Shetty H, Babu S, et al. Human Papilloma Virus Associated Squamous Cell Carcinoma of the Head and Neck. *Journal of Sexually Transmitted Diseases* 2015;**2015**:1–5. doi:10.1155/2015/791024

19

Spurgeon ME, Lambert PF. Merkel cell polyomavirus: A newly discovered human virus with oncogenic potential. *Virology* 2013;**435**:118–30. doi:10.1016/j.virol.2012.09.029

20

Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell polyomavirus. *Current Opinion in Virology* 2015;**11**:38–43. doi:10.1016/j.coviro.2015.01.009

21

Schinzari V, Barnaba V, Piconese S. Chronic hepatitis B virus and hepatitis C virus infections and cancer: synergy between viral and host factors. *Clinical Microbiology and Infection* 2015;**21**:969–74. doi:10.1016/j.cmi.2015.06.026

22

Lingyun Geng. Epstein-Barr Virus-associated lymphoproliferative disorders: experimental and clinical developments. *International Journal of Clinical and Experimental Medicine* 2015;**8**.<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658837/>

23

Weiss RA, Vogt PK. 100 years of Rous sarcoma virus. *The Journal of Experimental Medicine* 2011;**208**:2351–5. doi:10.1084/jem.20112160

24

Matsuoka M, Jeang K-T. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. *Oncogene* 2011;**30**:1379–89. doi:10.1038/onc.2010.537

25

Pierangeli A, Antonelli G, Gentile G. Immunodeficiency-associated viral oncogenesis. *Clinical Microbiology and Infection* 2015;**21**:975–83. doi:10.1016/j.cmi.2015.07.009

26

Reichert JM. Antibodies to watch in 2017. *mAbs* 2017;**9**:167–81. doi:10.1080/19420862.2016.1269580

27

Reichert JM. Antibodies to watch in 2016. *mAbs* 2016;**8**:197–204. doi:10.1080/19420862.2015.1125583

28

Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. *mAbs* 2015;**7**:9–14. doi:10.4161/19420862.2015.989042

29

Reichert JM. Marketed therapeutic antibodies compendium. *mAbs* 2012;**4**:413–5. doi:10.4161/mabs.19931

30

Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Therapy* 2002;**9**:967–78. doi:10.1038/sj.cgt.7700537

31

Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. *Nature Biotechnology* 2012;**30**:658–70. doi:10.1038/nbt.2287

32

Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. *Nature Reviews Drug Discovery* 2015;**14**:642–62. doi:10.1038/nrd4663

33

Larson C, Oronsky B, Scicinski J, et al. Going viral: a review of replication-selective oncolytic adenoviruses. *Oncotarget* 2015;**6**. doi:10.18632/oncotarget.5116

34

Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology* 2012;**12**:269–81. doi:10.1038/nri3191

35

Gill S, June CH. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. *Immunological Reviews* 2015;**263**:68–89. doi:10.1111/imr.12243

36

Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street. *The Journal of Immunology* 2015;**195**:755–61. doi:10.4049/jimmunol.1500751

37

Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. *Nature Reviews Cancer* 2012;**12**:265–77. doi:10.1038/nrc3258